Figure 5.
FACS analysis of PBMCs based on treatment response. (A) CD8+/PD-1+/Ki-67+prior to treatment. (B) Alteration in CD8+/PD-1+/Ki-67+from baseline to the early phase (after two cycles) of treatment. (C) CD8+/PD-1-/Ki-67+prior to treatment. (B) Alteration in CD8+/PD-1-/Ki-67+ from baseline to the early phase of treatment.
